← Back to feedRead original →
VERIFIEDET Finance·positive
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company
AI Summary
- ·Aurobindo Pharma's US subsidiary received Federal Trade Commission approval for the $250 million acquisition of Lannett Company.
- ·The acquisition is anticipated to be finalized by June 2026.
- ·The deal is expected to enhance Aurobindo's complex generics and controlled substances offerings and immediately increase earnings per share.